The relationship between anti-cyclic citrullinated peptide and bone mineral density and radiographic damage in patients with rheumatoid arthritis

Scandinavian Journal of Rheumatology

Volumn 37, Issue 5, 2008, Pages 337-342

  Guler, H ^a   Turhanoglu, A D ^a   Ozer, B ^a   Ozer, C ^a   Balci, A ^a  

^a MUSTAFA KEMAL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; BONE DENSITY; BONE RADIOGRAPHY; BONE TURNOVER; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEMUR; FUNCTIONAL STATUS; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; JOINT CAVITY; LOW DRUG DOSE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; SCORING SYSTEM;

ABSORPTIOMETRY, PHOTON; ADULT; ANTIBODIES, ANTI-IDIOTYPIC; ARTHRITIS, RHEUMATOID; BONE DENSITY; COLLAGEN TYPE I; FEMALE; FEMUR; HUMANS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOPOROSIS; PEPTIDES; PEPTIDES, CYCLIC; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 52949111438     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.1080/03009740801998812     Document Type: Article

References (39)

1. Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 2004;2(Suppl 22):1-12.
2. Spector TD, Hall GM, McCloskey EV, Kanis JA. Risk of vertebral fracture in women with rheumatoid arthritis. Br Med J 1993;306:558.
3. Rehman Q, Lane NE. Bone loss: therapeutic approaches for preventing bone loss in inflammatory arthritis. Arthritis Res 2001;3:221-7.
4. Momohara S, Okamoto H, Yago T, Furuya T, Nanke Y, Kotake S, et al. The study of bone mineral density and bone turnover markers in postmenopausal women with active rheumatoid arthritis. Mod Rheumatol 2005;15:410-14.
5. Jensen T, Hansen M, Madsen JC, Kollerup G, Stoltenberg M, Florescu A, et al. Serum levels of parathyroid hormone and markers of bone metabolism in patients with rheumatoid arthritis. Relationship to disease activity and glucocorticoid treatment. Scand J Clin Lab Invest 2001;61:491-501.
6. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43:155-63.
7. Rantapaa-Dahlqvist S. Diagnostic and prognostic significance of autoantibodies in early rheumatoid arthritis. Scand J Rheumatol 2005;34:83-96.
8. Kwok JS, Hui KH, Lee TL, Wong W, Lau YL, Wong RW, et al. Anti-cyclic citrullinated peptide: diagnostic and prognostic values in juvenile idiopathic arthritis and rheumatoid arthritis in a Chinese population. Scand J Rheumatol 2005;34:359-66.
9. Vossenaar ER, Zendman AJ, Van Venrooij WJ. Citrullination, a possible functional link between susceptibility genes and rheumatoid arthritis. Arthritis Res Ther 2004;6:1-5.
10. Nikolaisen C, Rekvig OP, Nossent HC. Diagnostic impact of contemporary biomarker assays for rheumatoid arthritis. Scand J Rheumatol 2007;36:97-100.
11. Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van't Hof M, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000;43:1831-5.
12. Goldbach-Mansky R, Lee J, McCoy A, Hoxworth J, Yarboro C, Smolen JS, et al. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res 2000;2:236-43.
13. Bizzaro N, Mazzanti G, Tonutti E, Villalta D, Tozzoli R. Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem 2001;47:1089-93.
14. Bas S, Perneger TV, Seitz M, Tiercy JM, Roux-Lombard P, Guerne PA. Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors. Rheumatology 2002;41:809-14.
15. van Jaarsveld CH, ter Borg EJ, Jacobs JW, Schellekens GA, Gmelig-Meyling FH, van Booma-Frankfort C, et al. The prognostic value of the antiperinuclear factor, anticitrullinated peptide antibodies and rheumatoid factor in early rheumatoid arthritis. Clin Exp Rheumatol 1999;17:689-97.
16. Meyer O, Labarre C, Dougados M, Goupile Ph, Cantagrel A, Dubois A, et al. Anti-citrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five-year radiographic damage. Ann Rheum Dis 2003;62:120-6.
17. van der Heide A, Remme CA, Hofman DM, Jacobs JWG, Bijlsma JW. Prediction of progression of radiologic damage in newly diagnosed rheumatoid arthritis. Arthritis Rheum 1995;38:1466-74.
18. O'Dell JR. Rheumatoid arthritis: the clinical picture. In Koopman WJ, Moreland LW, editors. Arthritis and allied conditions: a textbook of rheumatology, vol. 1. Philadelphia: Lippincott Williams & Wilkins, 2005: 1165-94.
19. Bongi SM, Manetti R, Melchiorre D, Turchini S, Boccaccini P, Vanni L, et al. Anti-cyclic citrullinated peptide antibodies are highly associated with severe bone lesions in rheumatoid arthritis anti-CCP and bone damage in RA. Autoimmunity 2004;37:495-501.
20. Arnett FC, Edworthy SM, Bloch DA, Meshane DJ, Fries JF, Cooper NS. The American Rheumatism Association 1987 criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
21. Sharp JT, Lidsky MD, Collins LC, Moreland J. Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum 1971;14:706-20.
22. Sharp JT, Young DY, Bluhm GB, Brook A, Brower AC, Corbett M, et al. How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? Arthritis Rheum 1985;28:1326-35.
23. van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998;41:1845-50.
24. Carson DA, Chen PP, Fox RI, Kipps TJ, Jirik F, Goldfien RD, et al. Rheumatoid factor and immune networks. Annu Rev Immunol 1987;5:109-26.
25. Agrawal S, Misra R, Aggarwal A. Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA. Clin Rheumatol 2007;26:201-4.
26. Glasnovic M, Bosnjak I, Vcev A, Soldo I, Glasnovic-Horvatic E, Soldo-Butkovic S, et al. Anti-citrullinated antibodies, radiological joint damages and their correlations with disease activity score (DAS 28). Coll Antropol 2007;31:345-8.
27. Shovman O, Gilburd B, Zandman-Goddard G, Sherer Y, Orbach H, Gerli R, et al. The diagnostic utility of anti-cyclic citrullinated peptide antibodies, matrix metalloproteinase-3, rheumatoid factor, erythrocyte sedimentation rate, and C-reactive protein in patients with erosive and nonerosive rheumatoid arthritis. Clin Dev Immunol 2005;12:197-202.
28. del Val del Amo N, Ibanez Bosch R, Fito Manteca C, Gutierrez Polo R, Loza Cortina E. Anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: relation with disease aggressiveness. Clin Exp Rheumatol 2006;24:281-6.
29. Mewar D, Coote A, Moore DJ, Marinou I, Keyworth J, Dickson MC, et al. Independent association of anti-cyclic citrullinated peptide antibodies and rheumatoid factor with radiographic severity of rheumatoid arthritis. Arthritis Res Ther 2006;8:R128.
30. Forslind K, Ahlmen M, Eberhardt K, Hafström I, Svensson B. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 2004;63:1090-5.
31. Berglin E, Johansson T, Sundin U, Jidell E, Wadell G, Hallmans G, et al. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgARF at disease onset. Ann Rheum Dis 2006;65:453-8.
32. Machold KP, Stamm TA, Nell VP, Pflugbeil D, Aletaha D, Steiner G, et al. Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology 2007;46:342-9.
33. Forslind K, Vincent C, Serre G, Svensson B. Antifilaggrin antibodies in early rheumatoid arthritis may predict radiological progression. Scand J Rheumatol 2001;30:221-4.
34. Sinigaglia R, Nervetti A, Mela Q, Bianchi G, Del Puente A, Di Munno O, et al. A multicenter cross-sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass inRheumatoid Arthritis. J Rheumatol 2000;27:2582-9.
35. Forsblad D'Elia H, Larsen A, Waltbrand E, Kvist G, Mellstrom D, Saxne T, et al. Radiographic joint destruction in postmenopausal rheumatoid arthritis is strongly associated with generalised osteoporosis. Ann Rheum Dis 2003;62:617-23.
36. Oelzner P, Müller A, Deschner F, Hüller M, Abendroth K, Hein G, et al. Relationship between disease activity and serum levels of vitamin D metabolites and PTH in rheumatoid arthritis. Calcif Tissue Int 1998;62:193-8.
37. Kastbom A, Strandberg G, Lindroos A, Skogh T. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA Project). Ann Rheum Dis 2004;63:1085-9.
38. Vencovsky J, Machacek S, Sedova L, Kafkova J, Gatterova J, Pesakova V, et al. Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 2003;62:427-30.
39. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 2005;7:R949-58.